Ilias Goranitis

What I do

I establish what health technologies are worth, particularly genomic and precision medicine technologies, and turn that evidence into decisions health systems can defend. That means costing what things actually cost, measuring benefits conventional health economics misses, and building the case in the form the decision-maker needs it.

Decisions this work has supported

• Four genomic tests listed on Australia’s Medicare Benefits Schedule. Economic evidence within approved MSAC applications for inheritable cardiac rhythm disorders, heritable kidney disease, mitochondrial disorders and childhood genetic hearing impairment. Over 2,000 families have since accessed publicly funded testing.
• Rapid genomic testing for critically ill children, approved by the Independent Hospital Pricing Authority. Expected to yield 200+ additional diagnoses a year and around $7 million in annual savings.
• The WHO investment case for genomics. Led the WHO-commissioned evidence review informing the case for enabling access to genomics and precision medicine globally.
• International guidance on postpartum haemorrhage. Health economic analysis alongside the E-MOTIVE trial (210,000 women across four countries) informed the WHO Roadmap to 2030 and a $0.5 billion Gates Foundation commitment.
• NICE guideline NG126, updated twice on evidence this work contributed. Reported clinical use of progesterone for early pregnancy bleeding rose from 13% to 86%.
• Three sets of international clinical guidelines cite this work: European Society of Cardiology, Asia Pacific Heart Rhythm Society and Heart Rhythm Society, and the Japanese Circulation Society.

Standing appointments & committees

• Member, WHO Human Genomics Expert Working Group, Western Pacific Region
• Founding and Lead Convener, iHEA Economics of Genomics and Precision Medicine Special Interest Group (130 members)
• Health Economics Lead, Australian Genomics (2018 to 2025); Member, National Steering Committee and Policy Network
• Health Economics Lead, International Partnership on Precision Child Health
• Panel member, Cancer Australia Expert Cancer Control Panel
• Expert advisor on genomics research prioritisation to the UK Department of Health, the Department of Industry, Innovation and Science, and the British Heart Foundation
• Member, Industry Genomics Network Alliance (InGeNA)

Education

• PhD Health Policy and Economics, University of Athens
• MSc International Health Policy and Economics, London School of Economics
• MSc Healthcare Management and Evaluation · BSc Healthcare Management, University of Athens
• Previously Senior Research Fellow and Deputy Director of Teaching, Health Economics Unit, University of Birmingham; seconded to NICE (2012)